Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 17/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7686408 | 0.87 | ADRA2A (0.65) | PTGIRADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL4689825 | 0.86 | ADRA2A (0.64) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL4689671 | 0.85 | ADRA2A (0.68) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL5803719 | 0.82 | PTGIR (1.00) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL7685597 | 0.81 | ADRA2A (0.70) | PTGIRADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL4689116 | 0.80 | ADRA2A (0.68) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL5805023 | 0.78 | PTGIR (0.71) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL5802923 | 0.78 | PTGIR (1.00) | PTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL7685721 | 0.78 | ADRA2A (0.61) | PTGIRADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL5806185 | 0.77 | PTGIR (0.97) | PTGIRADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656350-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | claimed |
| WO-2005005394-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | claimed |
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | TBXA2R, MRGPRX2, MRGPRX1 | PTGIR 15/4885ADRA2A 93/4885ADRA2B 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.